Price
No data yet.
Social Signal Score
Analyst Ratings
1 analystRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Lyn Baranowski
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 55
- Beta
- -1.13
- Country
- US
Financials
AVLN has only 2 quarterly periods on file — the charts below show the full history available.
Net Income
$-28.93MEBITDA
$-31.18MFree Cash Flow
$-26.34MEPS (diluted)
$-0.65Shares Outstanding (diluted)
44.33M+6.0%Operating Expenses
$31.18MCash & Debt
$352.43MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-85.20M | $-2.04 |
Valuation
AVLNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (5)
- Newsglobenewswire.com·15d ago·Neutral
Avalyn Publishes Phase 1 Data Highlighting AP02's Lung-Targeted Delivery and Encouraging Safety Profile Results validate Avalyn's approach of delivering established antifibrotic medicines directly to the lungs to maximize local exposure while limiting systemic exposure and improving tolerability
View source ↗ - Newsglobenewswire.com·19d ago·Negative
Avalyn Appoints Robert J. Meyer, MD, to its Board of Directors BOSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN) (“Avalyn” or the “Company”), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced the appointment of Robert (Bob) J. Meyer, MD, a distinguished pulmonary physician and former senior U.S. Food and Drug Administration (“FDA”) leader, to its Board of Di…
View source ↗ - Newsglobenewswire.com·28d ago·Neutral
… reduce logistical burden may support engagement in future pulmonary fibrosis clinical studies BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced new data demonstrating predicted aerosol distribution of AP01 and survey data highlighting patient perspectives on participation in clinical studies for idiopathic …
View source ↗ - Newsglobenewswire.com·42d ago·Neutral
Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026 Presentations describe integration of patient perspective into clinical trial design and data modeling AP01 distribution in the lungs Presentations describe integration of patient perspective into clinical trial design and data modeling AP01 distribution in the lungs
View source ↗ - Newsglobenewswire.com·55d ago·Neutral
Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights Completed enrollment of MIST global Phase 2b trial of AP01 with 398 patients; topline data expected in the second half of 2027 Two abstracts accepted for presentation at the European Respiratory Society (ERS) Congress, including data modeling AP01 lung tissue distribution Ended the second quarter of 2026 with $413.5 million in cash, cash equivalents and marketable securities; cash runway projected into 2029 BOSTO
View source ↗
Earnings
Typical surprise -145.7% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.98 vs $-0.78miss
- Wed, Jun 3$-21.83 vs $-5.98miss
Estimates and results for AVLN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in AVLN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.